Literature DB >> 9719414

Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells.

I V Balyasnikova1, S M Danilov, V R Muzykantov, A B Fisher.   

Abstract

Previous work has suggested that not all immunoreactive angiotensin-converting enzyme (ACE) in tissues or cells is in a biologically active state. We have explored this possibility in cultured human umbilical vein endothelial cells (HUVEC), one of the most widely studied in vitro endothelial cell systems. Our approach included characterization of the effect of increasing passage number on ACE activity and expression of immunoreactive ACE at the single cell level, the subcellular compartmentalization of active ACE, and the effect of phorbol ester (PMA) treatment. We found that both ACE activity and expression of ACE antigen were downregulated by cultivation (30% of ACE-positive cells at seventh passage vs. 90% in primary culture). ACE downregulation is specific (number of CD31-positive cells did not change with cultivation) and correlated with downregulation of factor VIII-antigen. The percentage of ACE-positive cells in permeabilized HUVEC at third passage was almost twice that in nonpermeabilized HUVEC (90% vs. 50%), indicating that HUVEC contain intracellular immunoreactive ACE. ACE activity, however, was similar when measured in intact cells and in cell lysates. Moreover, diazonium salt of sulfanilic acid (DASA), a membrane-impermeable ACE inhibitor, inhibited ACE activity in intact cells and in cell lysates at the same extent, thus implying that intracellular ACE is inactive. PMA (100 nM) treatment increased the percentage of ACE-positive cells at third passage from 57 to 96%. ACE activity was increased 3-fold in cell and 1.5-fold in the culture medium of PMA-treated cells. Analysis of ACE activity in intact monolayers and cell lysates of control and PMA-treated cells revealed that all enzymatically active ACE in PMA-treated cells is localized on the plasma membrane and acts as an ectoenzyme. We conclude that expression of ACE by HUVEC is downregulated by repeated passage in culture but can be restored by PMA treatment. In addition, ACE expression is heterogeneous between neighboring cells, and total immunoreactive ACE protein associated with HUVEC includes an inactive pool of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719414     DOI: 10.1007/s11626-998-0114-x

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.723


  36 in total

1.  Evaluation of long-term cultured endothelial cells as a model system for studying vascular ageing.

Authors:  N Hasegawa; M Yamamoto; T Imamura; Y Mitsui; K Yamamoto
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

2.  Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence.

Authors:  U S Ryan; J W Ryan; C Whitaker; A Chiu
Journal:  Tissue Cell       Date:  1976       Impact factor: 2.466

3.  Characteristics of monocyte angiotensin-converting enzyme (ACE) induction by dexamethasone.

Authors:  Z Vuk-Pavlović; T J Kreofsky; M S Rohrbach
Journal:  J Leukoc Biol       Date:  1989-06       Impact factor: 4.962

4.  Kinins and angiotensins. Angiotensin I converting enzyme (kininase II) in endothelial cells cultured from human pulmonary arteries and veins.

Authors:  A R Johnson; W W Schulz; L A Noguiera; E G Erdös
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

5.  Involvement of second messenger systems in stimulation of angiotensin converting enzyme of bovine endothelial cells.

Authors:  Y Dasarathy; B L Fanburg
Journal:  J Cell Physiol       Date:  1991-08       Impact factor: 6.384

6.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

Authors:  S C Thornton; S N Mueller; E M Levine
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

7.  Expression of angiotensin I-converting enzyme in the human gastric HGT-1 cell line.

Authors:  I Nonotte; M F Laliberté; N Rémy-Heintz; F Laliberté; C Chevillard
Journal:  Regul Pept       Date:  1995-11-10

8.  Bovine angiotensin converting enzyme cDNA cloning and regulation. Increased expression during endothelial cell growth arrest.

Authors:  S Y Shai; R S Fishel; B M Martin; B C Berk; K E Bernstein
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

9.  Regulation of prostaglandin production and ectoenzyme activities in cultured aortic endothelial cells.

Authors:  C N Chesterman; A Ager; J L Gordon
Journal:  J Cell Physiol       Date:  1983-07       Impact factor: 6.384

10.  A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions.

Authors:  W A Muller; C M Ratti; S L McDonnell; Z A Cohn
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  10 in total

1.  Umbilical cord endothelial cells expressing large T antigen: comparison with primary cultures and effect of cell age.

Authors:  U Fitzgerald; S Hettle; C MacDonald; J S McLean
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

2.  Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface.

Authors:  Irina V Balyasnikova; Eric H Karran; Ronald F Albrecht; Sergei M Danilov
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

3.  Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain.

Authors:  Sergei M Danilov; Sergey Kalinin; Zhenlong Chen; Elena I Vinokour; Andrew B Nesterovitch; David E Schwartz; Olivier Gribouval; Marie-Claire Gubler; Richard D Minshall
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

4.  LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells.

Authors:  M I Hermanns; A M Müller; M Tsokos; C J Kirkpatrick
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-29       Impact factor: 2.416

5.  Conformational changes of blood ACE in chronic uremia.

Authors:  Maxim N Petrov; Valery Y Shilo; Alexandr V Tarasov; David E Schwartz; Joe G N Garcia; Olga A Kost; Sergei M Danilov
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

6.  An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding.

Authors:  Sergei M Danilov; Kerry Gordon; Andrew B Nesterovitch; Heinrich Lünsdorf; Zhenlong Chen; Maricela Castellon; Isolda A Popova; Sergey Kalinin; Emma Mendonca; Pavel A Petukhov; David E Schwartz; Richard D Minshall; Edward D Sturrock
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

Review 7.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

8.  Lysozyme and bilirubin bind to ACE and regulate its conformation and shedding.

Authors:  Sergei M Danilov; Heinrich Lünsdorf; Henry T Akinbi; Andrew B Nesterovitch; Yuliya Epshtein; Eleftheria Letsiou; Olga V Kryukova; Tobias Piegeler; Elena Z Golukhova; David E Schwartz; Randal O Dull; Richard D Minshall; Olga A Kost; Joe G N Garcia
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  The anticoagulant effect of PGI2S and tPA in transgenic umbilical vein endothelial cells is linked to up-regulation of PKA and PKC.

Authors:  Jian-Hua Wang; Lin-Jing Yuan; Zhi-Min Zhong; Zhe-Sheng Wen; Jian-Ming Deng; Rong-Xin Liang; Min Zheng
Journal:  Int J Mol Sci       Date:  2014-02-19       Impact factor: 5.923

Review 10.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Authors:  Matthias Pinter; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.